STOCK TITAN

Arrowhead (ARWR) Files Form 144 for 611-Share Sale on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filed for ARWR reports a proposed sale of 611 common shares through Merrill Lynch on the NASDAQ with an aggregate market value of $12,190.05 and 138,257,550 shares outstanding. The notice specifies an approximate sale date of 08/13/2025.

The filing lists the acquisition history for the shares being sold: grants received as compensation on 01/04/2022 (3,485), 01/02/2023 (15,802), 01/04/2023 (12,557), 01/04/2024 (1,167), 01/08/2024 (4,950) and 01/04/2025 (27,271), with the named transferor in those records shown as James Hamilton. The form indicates no securities sold in the past three months and includes the required representation that the seller does not possess undisclosed material information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small proposed sale disclosed; details show shares were received as compensation over multiple years.

The filing documents a proposed sale of 611 common shares via Merrill Lynch on NASDAQ with an aggregate market value of $12,190.05 and outstanding shares of 138,257,550. The seller's acquisition history is fully listed and characterized as compensation from James Hamilton on specific dates from 2022–2025. The notice also records that no other securities were sold in the prior three months and includes the standard representation regarding material nonpublic information. For investors, this is a routine insider sale disclosure rather than a corporate operational update.

TL;DR: Compliance-focused disclosure showing insider-originated compensation shares and a planned brokered sale.

The Form 144 supplies the regulatory detail necessary for a proposed sale: broker name (Merrill Lynch), exchange (NASDAQ), number of shares (611), aggregate market value ($12,190.05) and the acquisition trail for those shares labeled as compensation with James Hamilton identified as the source across multiple dates. The filing also asserts the signer is unaware of undisclosed material adverse information. This presentation aligns with routine governance and disclosure expectations for executive or insider sales.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ARWR Form 144 disclose?

The notice discloses a proposed sale of 611 common shares via Merrill Lynch on NASDAQ with an aggregate market value of $12,190.05 and 138,257,550 shares outstanding.

When is the approximate sale date listed on the ARWR Form 144?

The filing lists the approximate date of sale as 08/13/2025.

How were the shares being sold acquired according to the filing?

The shares were acquired as compensation on multiple dates: 01/04/2022 (3,485), 01/02/2023 (15,802), 01/04/2023 (12,557), 01/04/2024 (1,167), 01/08/2024 (4,950), and 01/04/2025 (27,271).

Who is named in the filing as the source of the acquired shares?

The acquisition table names James Hamilton as the person from whom the compensation shares were listed as acquired.

Does the filing report any securities sold by the person in the past three months?

No. The filing's section on sales during the past three months states Nothing to Report.
Arrowhead Pharma

NASDAQ:ARWR

ARWR Rankings

ARWR Latest News

ARWR Latest SEC Filings

ARWR Stock Data

9.24B
129.83M
4.43%
77.49%
9.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA